Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Suspended Early Phase 1 Interventional

Using Aspirin to Improve Immunological Features of Ovarian Tumors

ClinicalTrials.gov ID: NCT05080946

Public ClinicalTrials.gov record NCT05080946. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 7:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Pilot Study to Assess the Efficacy of Aspirin to Improve Immunological Features of Ovarian Tumors

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of the study is to evaluate the effectiveness of aspirin with neoadjuvant chemotherapy for decreasing markers of immune suppression in the tumor at interval debulking surgery, in women with diagnosed ovarian, fallopian tube, or peritoneal carcinoma

Study identification

NCT ID
NCT05080946
Recruitment status
Suspended
Study type
Interventional
Phase
Early Phase 1
Enrollment
100 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 2, 2021 (Actual)
Primary completion
Nov 2026 (Estimated)
Completion
Dec 2026 (Estimated)
Last update posted
Sep 15, 2026

2021 – 2026

United States locations

U.S. sites
4
U.S. states
3
U.S. cities
4
Facility City State ZIP Site status
Moffitt Cancer Center Tampa Florida 33612 —
Oregon Health and Science University Portland Oregon 97239 —
University of Virginia Comprehensive Cancer Center Charlottesville Virginia 22903 —
Inova Schar Cancer Institute Fairfax Virginia 22031 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05080946, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 15, 2026 · Synced Oct 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT05080946 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →